Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

ARQT

Arcutis Biotherapeutics Inc

Feb 12 • 04:00PM ET

26.71

+0.12 0.45 %

Healthcare • Biotechnology • USA • NASD

Peers: BMRN ANAB RCUS BCRX TVRD CNTA DERM VERU SLNO KZIA

| Held by: VTI XBI IWM VXF IWO IBB VTWO SCHA VHT FESM

Index	RUT	P/E	-	EPS (ttm)	-0.35	Insider Own	12.05%	Shs Outstand	120.29M	Perf Week	2.45%
Market Cap	3.27B	Forward P/E	57.87	EPS next Y	0.46	Insider Trans	-3.28%	Shs Float	107.73M	Perf Month	2.53%
Enterprise Value	3.19B	PEG	-	EPS next Q	0.08	Inst Own	91.88%	Short Float	14.86%	Perf Quarter	11.15%
Income	-44.32M	P/S	10.29	EPS this Y	83.21%	Inst Trans	-6.36%	Short Ratio	8.59	Perf Half Y	70.89%
Sales	317.93M	P/B	20.33	EPS next Y	336.97%	ROA	-10.97%	Short Interest	16.01M	Perf YTD	-8.02%
Book/sh	1.31	P/C	17.10	EPS next 5Y	-	ROE	-28.17%	52W High	31.77 -15.93%	Perf Year	102.20%
Cash/sh	1.56	P/FCF	-	EPS past 3/5Y	34.80% -0.98%	ROIC	-16.36%	52W Low	11.15 139.55%	Perf 3Y	60.32%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	89.96%	Volatility	3.89% 3.80%	Perf 5Y	-23.86%
Dividend TTM	-	EV/Sales	10.05	EPS Y/Y TTM	80.35%	Oper. Margin	-12.03%	ATR (14)	1.10	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.28	Sales Y/Y TTM	129.21%	Profit Margin	-13.94%	RSI (14)	49.21	Recom	1.25
Dividend Gr. 3/5Y	- -	Current Ratio	3.50	EPS Q/Q	116.70%	SMA20	1.73%	Beta	1.67	Target Price	31.75
Payout	-	Debt/Eq	0.72	Sales Q/Q	121.69%	SMA50	-4.37%	Rel Volume	0.59	Prev Close	26.59
Employees	342	LT Debt/Eq	0.71	Earnings	Feb 25 AMC	SMA200	32.58%	Avg Volume	1.86M	Price	26.71
IPO	Jan 31, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	164.10% 14.08%	Trades		Volume	1,099,850	Change	0.45%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-25-25	Initiated	Goldman	Neutral	$18
Dec-30-24	Initiated	H.C. Wainwright	Buy	$19
Aug-28-24	Initiated	Jefferies	Buy	$15
Jan-03-24	Upgrade	Mizuho	Neutral → Buy	$4 → $8
Oct-26-23	Downgrade	Mizuho	Buy → Neutral	$57 → $4
Oct-13-23	Downgrade	Goldman	Buy → Neutral	$32 → $6
Sep-07-22	Initiated	Needham	Buy	$46
Mar-17-22	Initiated	Goldman	Buy	$45
Jun-30-21	Initiated	Mizuho	Buy	$58
May-27-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$52
Nov-09-20	Upgrade	Goldman	Neutral → Buy	$34 → $36
Oct-08-20	Initiated	Truist	Buy	$38
Feb-25-20	Initiated	Guggenheim	Buy	$36
Feb-25-20	Initiated	Goldman	Neutral	$30
Feb-25-20	Initiated	Cowen	Outperform	$55
Feb-25-20	Initiated	Cantor Fitzgerald	Overweight	$50

Show Previous Ratings

Feb-11-26 06:02PM	Arcutis Biotherapeutics Touts ZORYVE Expansion, New Indications and 2026 Cash-Flow Breakeven Goal (MarketBeat)
Feb-10-26 08:32AM	Implied Volatility Surging for Arcutis Biotherapeutics Stock Options (Zacks)
Feb-05-26 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-02-26 08:00AM	Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis (GlobeNewswire)
Jan-27-26 08:16AM	Arcutis Biotherapeutics announces termination of promotion agreement with Kowa (TipRanks)
08:00AM	Loading…
Jan-26-26 08:00AM	Arcutis Biotherapeutics, Inc. Announces Termination of Promotion Agreement with Kowa (GlobeNewswire)
Jan-22-26 04:00PM	Arcutis to Report Fourth Quarter and Full Year 2025 Financial Results and Present at Upcoming Investor Conference (GlobeNewswire)
Jan-21-26 08:00AM	Nationwide Survey Underscores Concerns with Use of Topical Steroids and Need for Long-Term Treatment Strategies Facing the 46 Million Americans with Chronic Inflammatory Skin Conditions (GlobeNewswire)
Jan-13-26 04:21AM	Strength Seen in ANI (ANIP): Can Its 10.6% Jump Turn into More Strength? (Zacks)
Jan-12-26 08:00AM	Arcutis Highlights 2026 Strategic Priorities and Anticipated Milestones (GlobeNewswire) -5.10%
Dec-19-25 09:40AM	Are Medical Stocks Lagging Compass Therapeutics, Inc. (CMPX) This Year? (Zacks)
Dec-18-25 03:43AM	Zacks Industry Outlook Arcutis, Amicus and ANI (Zacks)
Dec-17-25 02:19PM	5 Biotech Stocks to Watch for Potential Upside (Zacks)
Dec-14-25 09:35AM	This Biotech Stock Could Cure Your Portfolio's Pain (Motley Fool)
Dec-10-25 12:00PM	What Makes Arcutis Biotherapeutics, Inc. (ARQT) a Strong Momentum Stock: Buy Now? (Zacks)
04:00PM	Loading…
Dec-08-25 04:00PM	Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri (GlobeNewswire)
10:39AM	PRAX Stock Skyrockets 520% in 3 Months: Here's What You Need to Know (Zacks)
10:30AM	Incyte's Rare Blood Cancer Therapy Gets FDA's Breakthrough Status (Zacks)
Dec-05-25 10:37AM	ABSI Stock Up on Initiating Dosing in Androgenetic Alopecia Study (Zacks)
10:34AM	CAPR Stock Skyrockets 282% in a Week: Here's What You Need to Know (Zacks)
Dec-04-25 09:47AM	Zoetis Stock Plummets 24.8% YTD: Here's What You Need to Know (Zacks)
Dec-03-25 10:23AM	PCRX's Iovera Outperforms RFA Therapy in Pilot Study for Low Back Pain (Zacks)
10:01AM	AZN's Baxdrostat Gets FDA Priority Tag for Uncontrolled Hypertension (Zacks)
09:40AM	Is BrightSpring Health Services, Inc. (BTSG) Outperforming Other Medical Stocks This Year? (Zacks)
Dec-02-25 10:15AM	MIRM Enrolls First Patient in Phase II Fragile X Syndrome Study (Zacks)
10:12AM	Is the Options Market Predicting a Spike in Arcutis Biotherapeutics Stock? (Zacks)
10:09AM	JNJ Gets EU Nod for Imaavy in Generalized Myasthenia Gravis (Zacks)
Dec-01-25 11:41AM	ARCT Stock Plunges 59% in Three Months: Here's What You Need to Know (Zacks)
Nov-28-25 09:33AM	Netflix target cut, Five Below target raised: Wall Street's top analyst calls (The Fly)
Nov-25-25 11:10AM	NVO Stock Down as Rybelsus Misses Goals in 2 Alzheimer's Studies (Zacks)
10:43AM	Loading…
10:43AM	Biogen Inks Research Deal With Dayra to Boost Immunology Pipeline (Zacks)
Nov-21-25 03:47AM	Why Shares in Arcutis Biotherapeutics Surged Again This Week (Motley Fool) +7.90%
Nov-20-25 11:38AM	COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know (Zacks)
09:49AM	MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC (Zacks)
09:15AM	Arcutis Biotherapeutics, Inc. (ARQT) Soars to 52-Week High, Time to Cash Out? (Zacks)
Nov-19-25 10:06AM	VNDA Stock Jumps on Upbeat Tradipitant Data Cutting GLP-1 Side Effects (Zacks)
Nov-18-25 11:42AM	VTYX Stock Skyrockets 156% in a Month: Here's What You Need to Know (Zacks)
10:33AM	Alector Stock Plummets 63% in a Month: Here's What You Need to Know (Zacks)
Nov-17-25 09:41AM	Are Medical Stocks Lagging BrightSpring Health Services, Inc. (BTSG) This Year? (Zacks)
09:35AM	Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 20-Day Moving Average (Zacks)
08:00AM	FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 (GlobeNewswire)
Nov-15-25 08:00AM	CrowdStrike Leads Five Stocks To Watch Near Buy Points (Investor's Business Daily)
Nov-14-25 07:36AM	Kodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus (Zacks) +9.36%
Nov-13-25 09:08AM	Novartis' Phase III Malaria Study Meets Key Non-Inferiority Endpoint (Zacks)
08:00AM	Arcutis Completes Enrollment in INTEGUMENT-INFANT Phase 2 Study Evaluating ZORYVE (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis (GlobeNewswire)
Nov-11-25 10:37AM	Editas Q3 Loss Narrower Than Expected, Revenues Increase Y/Y (Zacks)
Nov-07-25 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
11:27AM	Novavax Q3 Earnings & Revenues Beat Estimates, '25 Sales View Raised (Zacks)
11:22AM	ESPR's Q3 Earnings Lag Estimates, Revenues Rise Y/Y, Stock Down (Zacks)
10:53AM	PBYI's Q3 Earnings & Revenues Beat Estimates, 2025 Sales View Raised (Zacks)
Nov-06-25 11:23AM	ACAD Q3 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth (Zacks)
11:18AM	TEVA Q3 Earnings & Revenues Beat, Austedo Sales View Raised, Stock Up (Zacks)
Nov-05-25 11:27AM	MIRM's Q3 Earnings & Revenues Beat Estimates, 2025 View Tightened (Zacks)
10:01AM	Corcept Q3 Earnings & Revenues Lag Estimates, '25 View Cut, Stock Down (Zacks)
09:55AM	Wall Street Analysts Believe Arcutis Biotherapeutics (ARQT) Could Rally 26.53%: Here's is How to Trade (Zacks)
Nov-04-25 10:26AM	TGTX's Q3 Earnings & Revenues Trump Estimates, 2025 View Raised (Zacks)
08:00AM	Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology (GlobeNewswire)
Oct-31-25 09:15AM	Arcutis Biotherapeutics, Inc. (ARQT) Hits Fresh High: Is There Still Room to Run? (Zacks)
Oct-30-25 12:00PM	What Makes Arcutis Biotherapeutics (ARQT) a New Strong Buy Stock (Zacks)
09:40AM	Is Grifols (GRFS) Stock Outpacing Its Medical Peers This Year? (Zacks)
09:15AM	Mother-Daughter Duo, Tori Spelling and Stella McDermott, Partner With Arcutis Biotherapeutics in the Free to Be Me Campaign, Urging People With Inflammatory Skin Conditions to Speak With Their Healthcare Provider About Long-Term Treatments (GlobeNewswire)
08:00AM	Arcutis Launches ZORYVE (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5 (GlobeNewswire)
Oct-29-25 09:08AM	Arcutis (ARQT) Soars to Record High on Swing to Profitability, 'More-Than-Double' Revenues (Insider Monkey)
Oct-28-25 12:00PM	Here's Why This Biotherapeutics Company's Stock Surged Higher by 30% Today (Motley Fool) +27.04%
11:37AM	Arcutis Tops A Profit-Taking Zone After Smashing Forecasts. But There Was Another Surprise. (Investor's Business Daily)
09:35AM	Arcutis Biotherapeutics, Inc. (ARQT) Q3 Earnings and Revenues Surpass Estimates (Zacks)
08:30AM	Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-27-25 04:00PM	Arcutis to Present at Upcoming Investor Conferences (GlobeNewswire)
09:30AM	What To Expect From Arcutis Biotherapeutics Inc (ARQT) Q3 2025 Earnings (GuruFocus.com)
Oct-24-25 08:00AM	Arcutis to Present New Quality of Life and Long-Term Data with ZORYVE (roflumilast) Cream 0.15% and 0.05% for the Treatment of Atopic Dermatitis at the Fall Clinical Dermatology Conference (GlobeNewswire)
Oct-21-25 10:00AM	Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Oct-06-25 08:00AM	FDA Approves Arcutis' ZORYVE (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5 (GlobeNewswire)
06:41AM	Tarsus Pharmaceuticals (TARS) Moves 10.9% Higher: Will This Strength Last? (Zacks)
Oct-03-25 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.26%
Oct-01-25 09:15AM	Arcutis Biotherapeutics, Inc. (ARQT) Hit a 52 Week High, Can the Run Continue? (Zacks)
Sep-29-25 04:00PM	Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025 (GlobeNewswire) +5.98%
11:38AM	Biotech Leader Arcutis Is Breaking Out, Up Nearly 36% in 2025 (Investor's Business Daily)
09:40AM	Are Medical Stocks Lagging Arcutis Biotherapeutics (ARQT) This Year? (Zacks)
Sep-25-25 12:00PM	Here's Why Arcutis Biotherapeutics, Inc. (ARQT) is a Great Momentum Stock to Buy (Zacks)
Sep-17-25 04:00AM	Arcutis To Present Multiple New ZORYVE (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress (GlobeNewswire)
Sep-16-25 09:00AM	Allure Magazine Honors Arcutis' ZORYVE (roflumilast) with Prestigious Best of Beauty Breakthrough Award (GlobeNewswire)
Sep-12-25 09:40AM	Are Medical Stocks Lagging AxoGen (AXGN) This Year? (Zacks)
Sep-11-25 11:17AM	Arcutis Biotherapeutics, Inc. (ARQT) Eyes Pediatric Expansion for ZORYVE Cream (Insider Monkey)
Sep-10-25 12:20AM	Arcutis Biotherapeutics Submits Supplemental New Drug Application to FDA For ZORYVE (Insider Monkey)
Sep-05-25 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.80%
Sep-03-25 11:43AM	Arcutis Submits Supplemental New Drug Application for ZORYVE (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5 (GlobeNewswire)
Sep-01-25 09:55AM	Does Arcutis Biotherapeutics (ARQT) Have the Potential to Rally 45.81% as Wall Street Analysts Expect? (Zacks)
Aug-27-25 09:40AM	Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year? (Zacks)
Aug-25-25 06:33PM	3 Biotech Catalysts Present Major Opportunity (MarketBeat)
Aug-19-25 04:00PM	Arcutis to Present at Upcoming Investor Conferences (GlobeNewswire) -5.79%
Aug-15-25 10:06AM	This Eye Treatment Stock Sees Sales Spike 152% As Biotech Leaders Shine (Investor's Business Daily) +5.69%
Aug-14-25 09:55AM	Wall Street Analysts Predict a 44.79% Upside in Arcutis Biotherapeutics (ARQT): Here's What You Should Know (Zacks)
Aug-11-25 09:40AM	Are Medical Stocks Lagging Arcutis Biotherapeutics (ARQT) This Year? (Zacks)
Aug-08-25 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-06-25 05:10PM	Arcutis Biotherapeutics, Inc. (ARQT) Reports Q2 Loss, Beats Revenue Estimates (Zacks) -8.07%
04:00PM	Arcutis Announces Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Aug-05-25 09:49AM	Arcutis Biotherapeutics Inc (ARQT) Q2 2025: Everything You Need to Know Ahead of Earnings (GuruFocus.com) +5.54%
Jul-30-25 10:00AM	Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Jul-23-25 04:00PM	Arcutis to Report Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025 (GlobeNewswire)
Jul-17-25 12:28PM	Arcutis Stock Awaits Next Move In A Base; Its Skin Drug Sales Grew 196% (Investor's Business Daily)

Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its pipeline consists of topical treatments for plaque psoriasis, atopic dermatitis, hand eczema, vitiligo, scalp psoriasis, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne in June 2016 and is headquartered in Westlake Village, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Matsuda Masaru	See Remarks	Feb 02 '26	Sale	25.28	40,638	1,027,293	110,003	Feb 04 08:35 PM
Burnett Patrick	See Remarks	Feb 04 '26	Sale	25.81	9,794	252,748	80,651	Feb 04 07:30 PM
Burnett Patrick	See Remarks	Feb 02 '26	Sale	25.50	3,675	93,707	90,445	Feb 04 07:30 PM
Watanabe Todd	See Remarks	Feb 02 '26	Sale	25.50	19,833	505,710	721,306	Feb 04 07:25 PM
Vairavan Latha	SVP Chief Financial Officer	Feb 02 '26	Sale	25.50	1,320	33,658	63,607	Feb 04 07:24 PM
Welgus Howard G.	Director	Feb 02 '26	Sale	25.05	10,000	250,483	59,744	Feb 04 07:23 PM
Edwards Larry Todd	See Remarks	Feb 02 '26	Sale	25.50	2,052	52,323	148,865	Feb 04 07:21 PM
Patrick Burnett	Officer	Feb 04 '26	Proposed Sale	25.81	9,794	252,748		Feb 04 04:52 PM
Masaru Matsuda	officer	Feb 02 '26	Proposed Sale	25.28	40,638	1,027,275		Feb 02 06:19 PM
Todd Edwards	Officer	Feb 02 '26	Proposed Sale	25.50	2,052	52,323		Feb 02 06:17 PM
Latha Vairavan	Officer	Feb 02 '26	Proposed Sale	25.50	1,320	33,658		Feb 02 06:15 PM
Patrick Burnett	Officer	Feb 02 '26	Proposed Sale	25.50	3,675	93,707		Feb 02 05:48 PM
Todd Frank Watanabe	officer	Feb 02 '26	Proposed Sale	25.50	19,833	505,710		Feb 02 05:41 PM
Howard Welgus	Director	Feb 02 '26	Proposed Sale	25.05	10,000	250,483		Feb 02 05:04 PM
Burnett Patrick	See Remarks	Jan 05 '26	Sale	28.98	2,490	72,166	94,120	Jan 07 05:46 PM
Welgus Howard G.	Director	Jan 02 '26	Sale	28.96	10,000	289,606	69,744	Jan 06 05:31 PM
Patrick Burnett	Officer	Jan 05 '26	Proposed Sale	28.98	2,490	72,166		Jan 05 04:01 PM
Burnett Patrick	See Remarks	Dec 31 '25	Sale	29.20	1,697	49,560	96,610	Jan 02 06:12 PM
Howard Welgus	Director	Jan 02 '26	Proposed Sale	28.96	10,000	289,606		Jan 02 04:00 PM
Patrick Burnett	Officer	Dec 31 '25	Proposed Sale	29.21	1,697	49,561		Dec 31 04:01 PM
Burnett Patrick	See Remarks	Dec 15 '25	Option Exercise	3.64	11,500	41,860	109,807	Dec 17 05:53 PM
Burnett Patrick	See Remarks	Dec 15 '25	Sale	28.94	11,500	332,851	98,307	Dec 17 05:53 PM
Patrick Burnett	Officer	Dec 15 '25	Proposed Sale	28.94	11,500	332,851		Dec 15 04:07 PM
Matsuda Masaru	See Remarks	Dec 01 '25	Sale	30.23	1,657	50,091	150,641	Dec 03 05:24 PM
Welgus Howard G.	Director	Dec 01 '25	Sale	30.21	10,000	302,133	79,744	Dec 03 05:23 PM
Howard Welgus	Director	Dec 01 '25	Proposed Sale	30.21	10,000	302,133		Dec 01 04:07 PM
Masaru Matsuda	Officer	Dec 01 '25	Proposed Sale	30.23	1,657	50,091		Dec 01 04:06 PM
LIN SUE-JEAN	Director	Nov 24 '25	Option Exercise	8.31	25,272	210,011	52,007	Nov 25 06:27 PM
LIN SUE-JEAN	Director	Nov 24 '25	Sale	30.78	25,272	777,956	26,735	Nov 25 06:27 PM
Watanabe Todd	See Remarks	Nov 24 '25	Sale	30.36	48,945	1,485,755	740,537	Nov 24 06:45 PM
Watanabe Todd	See Remarks	Nov 21 '25	Sale	30.00	1,055	31,650	793,838	Nov 24 06:45 PM
Sue-Jean Lin	Director	Nov 24 '25	Proposed Sale	30.78	25,272	777,956		Nov 24 04:01 PM
Todd Franklin Watanabe	Officer	Nov 24 '25	Proposed Sale	30.36	48,945	1,485,755		Nov 24 03:55 PM
Matsuda Masaru	See Remarks	Nov 19 '25	Sale	28.29	2,550	72,135	151,476	Nov 21 06:34 PM
Gilbert Halley E	Director	Nov 20 '25	Option Exercise	7.51	12,220	91,772	38,655	Nov 21 06:21 PM
Gilbert Halley E	Director	Nov 20 '25	Sale	27.55	16,532	455,442	22,123	Nov 21 06:21 PM
Todd Franklin Watanabe	Officer	Nov 21 '25	Proposed Sale	30.00	1,055	31,650		Nov 21 04:49 PM
Halley Gilbert	Director	Nov 20 '25	Proposed Sale	27.55	16,532	455,442		Nov 20 04:24 PM
Masaru Matsuda	Officer	Nov 19 '25	Proposed Sale	28.29	2,550	72,133		Nov 19 04:20 PM
Krishnamohan Neha	Director	Nov 13 '25	Option Exercise	8.28	39,272	325,231	62,627	Nov 17 07:56 PM
Krishnamohan Neha	Director	Nov 13 '25	Sale	23.20	40,504	939,494	22,123	Nov 17 07:56 PM
Neha Krishnamohan	Director	Nov 13 '25	Proposed Sale	23.19	40,504	939,273		Nov 13 04:05 PM
Edwards Larry Todd	See Remarks	Nov 06 '25	Sale	25.16	29,131	732,927	150,193	Nov 10 05:42 PM
Burnett Patrick	See Remarks	Nov 06 '25	Option Exercise	3.64	17,250	62,790	115,575	Nov 10 05:41 PM
Burnett Patrick	See Remarks	Nov 06 '25	Sale	24.18	17,250	417,145	98,325	Nov 10 05:41 PM
Patrick Burnett	Officer	Nov 06 '25	Proposed Sale	24.18	17,250	417,145		Nov 06 05:49 PM
Burnett Patrick	See Remarks	Nov 05 '25	Sale	23.72	3,864	91,643	98,325	Nov 05 06:57 PM
Burnett Patrick	See Remarks	Nov 03 '25	Sale	24.72	2,622	64,806	102,189	Nov 05 06:57 PM
Welgus Howard G.	Director	Nov 03 '25	Sale	25.27	10,000	252,669	89,744	Nov 05 06:24 PM
Vairavan Latha	SVP Chief Financial Officer	Nov 03 '25	Sale	24.72	88	2,175	64,927	Nov 05 06:24 PM
Watanabe Todd	See Remarks	Nov 03 '25	Sale	24.72	11,547	285,399	794,893	Nov 05 06:23 PM
Matsuda Masaru	See Remarks	Nov 03 '25	Sale	24.72	7,208	178,156	154,026	Nov 05 06:23 PM
Patrick Burnett	Officer	Nov 05 '25	Proposed Sale	23.72	3,846	91,216		Nov 05 05:29 PM
Masaru Matsuda	Officer	Nov 03 '25	Proposed Sale	24.72	7,208	178,155		Nov 03 05:49 PM
Latha Vairavan	Officer	Nov 03 '25	Proposed Sale	24.72	88	2,175		Nov 03 05:48 PM
Todd Franklin Watanabe	Officer	Nov 03 '25	Proposed Sale	24.72	11,547	285,399		Nov 03 05:47 PM
Patrick Burnett	Officer	Nov 03 '25	Proposed Sale	24.72	2,622	64,806		Nov 03 05:47 PM
Howard Welgus	Director	Nov 03 '25	Proposed Sale	25.27	10,000	252,669		Nov 03 04:52 PM
Watanabe Todd	See Remarks	Oct 28 '25	Sale	25.03	40,000	1,001,032	806,440	Oct 30 07:02 PM
Todd F watanabe	officer	Oct 28 '25	Proposed Sale	25.03	40,000	1,001,033		Oct 28 04:06 PM
Edwards Larry Todd	See Remarks	Oct 02 '25	Sale	20.04	4,504	90,263	178,897	Oct 06 03:15 PM
Watanabe Todd	See Remarks	Oct 01 '25	Sale	19.33	24,261	469,074	867,179	Oct 03 05:02 PM
Watanabe Todd	See Remarks	Oct 02 '25	Sale	20.04	20,739	415,574	846,440	Oct 03 05:02 PM
Welgus Howard G.	Director	Oct 01 '25	Option Exercise	1.68	9,538	16,030	109,744	Oct 03 05:01 PM
Welgus Howard G.	Director	Oct 01 '25	Sale	18.92	10,000	189,227	99,744	Oct 03 05:01 PM
Todd Franklin Watanabe	Officer	Oct 02 '25	Proposed Sale	20.04	20,739	415,574		Oct 02 04:43 PM
Larry Todd Edwards	officer	Oct 02 '25	Proposed Sale	20.04	4,504	90,263		Oct 02 04:41 PM
Todd Franklin Watanabe	Officer	Oct 01 '25	Proposed Sale	19.33	24,261	469,074		Oct 01 05:35 PM
Howard Welgus	Director	Oct 01 '25	Proposed Sale	18.92	10,000	189,227		Oct 01 03:16 PM
Watanabe Todd	See Remarks	Sep 08 '25	Sale	17.54	9,625	168,799	891,944	Sep 10 06:21 PM
Watanabe Todd	See Remarks	Sep 09 '25	Sale	17.52	504	8,829	891,440	Sep 10 06:21 PM
Watanabe Todd	Officer	Sep 09 '25	Proposed Sale	17.52	504	8,829		Sep 09 03:17 PM
Matsuda Masaru	See Remarks	Sep 04 '25	Sale	16.16	36,130	583,716	161,234	Sep 08 05:14 PM
Watanabe Todd	Officer	Sep 08 '25	Proposed Sale	17.54	9,625	168,800		Sep 08 05:04 PM
Welgus Howard G.	Director	Sep 02 '25	Option Exercise	0.00	10,000	0	110,206	Sep 04 06:41 PM
Welgus Howard G.	Director	Sep 02 '25	Sale	15.64	10,000	156,383	100,206	Sep 04 06:41 PM
Matsuda Masaru	Officer	Sep 04 '25	Proposed Sale	16.16	36,130	583,716		Sep 04 04:21 PM
Welgus Howard G.	Director	Sep 02 '25	Proposed Sale	15.61	10,000	156,083		Sep 02 03:08 PM
Burnett Patrick	See Remarks	Aug 21 '25	Sale	15.57	2,438	37,969	104,811	Aug 21 09:32 PM
Burnett Patrick	See Remarks	Aug 19 '25	Sale	16.16	1,750	28,281	107,249	Aug 21 09:32 PM
Burnett Patrick	Officer	Aug 21 '25	Proposed Sale	15.57	2,438	37,969		Aug 21 05:27 PM
Burnett Patrick	Officer	Aug 19 '25	Proposed Sale	16.13	1,750	28,228		Aug 19 04:57 PM
Burnett Patrick	See Remarks	Aug 08 '25	Sale	14.03	3,847	53,988	108,999	Aug 12 05:04 PM
Topper David Joseph	Former Officer	Aug 08 '25	Proposed Sale	14.58	41,979	611,936		Aug 08 04:40 PM
Burnett Patrick	Officer	Aug 08 '25	Proposed Sale	14.03	3,847	53,989		Aug 08 04:10 PM
Topper David Joseph	Former Officer	Aug 06 '25	Proposed Sale	14.99	53,187	797,446		Aug 06 03:04 PM
Watanabe Todd	See Remarks	Aug 04 '25	Sale	14.33	11,547	165,429	901,569	Aug 05 06:29 PM
Burnett Patrick	See Remarks	Aug 04 '25	Sale	14.33	2,622	37,564	112,846	Aug 05 06:28 PM
Vairavan Latha	SVP Chief Financial Officer	Aug 04 '25	Sale	14.33	89	1,275	65,015	Aug 05 06:28 PM
Matsuda Masaru	See Remarks	Aug 04 '25	Sale	14.33	6,330	90,687	197,364	Aug 05 06:28 PM
Welgus Howard G.	Director	Aug 01 '25	Option Exercise	0.00	10,000	0	106,316	Aug 05 06:28 PM
Welgus Howard G.	Director	Aug 01 '25	Sale	14.30	10,000	142,982	100,206	Aug 05 06:28 PM
Watanabe Todd	Officer	Aug 04 '25	Proposed Sale	14.33	11,547	165,429		Aug 04 03:43 PM
Burnett Patrick	Officer	Aug 04 '25	Proposed Sale	14.33	2,622	37,564		Aug 04 03:42 PM
Matsuda Masaru	Officer	Aug 04 '25	Proposed Sale	14.33	6,330	90,687		Aug 04 03:40 PM
Vairavan Latha	Officer	Aug 04 '25	Proposed Sale	14.10	89	1,255		Aug 04 03:38 PM
Welgus Howard G.	Director	Aug 01 '25	Proposed Sale	14.30	10,000	142,982		Aug 01 04:20 PM
Burnett Patrick	See Remarks	Jul 10 '25	Option Exercise	0.00	23,000	0	138,468	Jul 14 04:02 PM
Burnett Patrick	See Remarks	Jul 14 '25	Option Exercise	0.00	5,750	0	121,218	Jul 14 04:02 PM
Burnett Patrick	See Remarks	Jul 10 '25	Sale	15.05	23,000	346,046	115,468	Jul 14 04:02 PM

Open in Screener

PCVX

Vaxcyte Inc

Feb 12 • 04:00PM ET

54.95

-0.40 -0.72 %

Healthcare • Biotechnology • USA • NASD

Peers: PFE MRNA BNTX NVAX AZN-D JNJ GSK ALNY NVCR VNDA

| Held by: VTI IWM VB XBI VBK VXF IWN IBB SCHA VTWO

Index	RUT	P/E	-	EPS (ttm)	-4.92	Insider Own	2.93%	Shs Outstand	141.91M	Perf Week	1.93%
Market Cap	7.80B	Forward P/E	-	EPS next Y	-6.13	Insider Trans	-0.51%	Shs Float	137.75M	Perf Month	19.40%
Enterprise Value	6.17B	PEG	-	EPS next Q	-1.53	Inst Own	97.74%	Short Float	8.68%	Perf Quarter	20.35%
Income	-657.20M	P/S	-	EPS this Y	-43.08%	Inst Trans	-3.93%	Short Ratio	8.17	Perf Half Y	74.17%
Sales	0.00M	P/B	2.47	EPS next Y	-12.73%	ROA	-19.53%	Short Interest	11.95M	Perf YTD	19.09%
Book/sh	22.25	P/C	4.56	EPS next 5Y	-20.61%	ROE	-20.83%	52W High	86.68 -36.61%	Perf Year	-35.67%
Cash/sh	12.06	P/FCF	-	EPS past 3/5Y	-25.42% -29.88%	ROIC	-22.12%	52W Low	27.66 98.66%	Perf 3Y	25.60%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.62% 6.50%	Perf 5Y	109.97%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-5.21%	Oper. Margin	-	ATR (14)	3.05	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.83	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	58.69	Recom	1.20
Dividend Gr. 3/5Y	- -	Current Ratio	8.83	EPS Q/Q	-87.44%	SMA20	3.31%	Beta	1.33	Target Price	102.11
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	12.73%	Rel Volume	0.72	Prev Close	55.35
Employees	414	LT Debt/Eq	0.03	Earnings	Feb 24 AMC	SMA200	39.18%	Avg Volume	1.46M	Price	54.95
IPO	Jun 12, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-26.03% -	Trades		Volume	1,049,144	Change	-0.72%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-07-26	Reiterated	Needham	Buy	$90 → $110
Sep-12-25	Initiated	Goldman	Neutral	$38
Apr-22-25	Initiated	Cantor Fitzgerald	Overweight
Dec-20-24	Initiated	Goldman	Buy	$135
Dec-07-23	Initiated	Mizuho	Buy	$69
Apr-18-23	Initiated	TD Cowen	Outperform
Jan-03-23	Reiterated	Needham	Buy	$52 → $58
Dec-15-22	Initiated	Guggenheim	Buy	$66
Nov-17-22	Initiated	BTIG Research	Buy	$69
Dec-29-21	Resumed	Jefferies	Buy	$50
Jun-24-21	Resumed	Jefferies	Buy	$50
Jul-07-20	Initiated	Needham	Buy	$40
Jul-07-20	Initiated	Cantor Fitzgerald	Overweight	$55
Jul-07-20	Initiated	BofA Securities	Buy	$37

Show Previous Ratings

Feb-11-26 04:05PM	Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines (GlobeNewswire)
Feb-10-26 04:05PM	Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026 (GlobeNewswire)
Feb-05-26 04:05PM	Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit (GlobeNewswire)
Feb-02-26 04:05PM	Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) +7.15%
Jan-29-26 11:33PM	Vaxcyte Announces Pricing of $550 Million Public Offering (GlobeNewswire)
04:06PM	Loading…
04:06PM	Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Jan-26-26 03:14AM	Evercore ISI Rates Vaxcyte Inc. (PCVX) as an Overweight Following CDC Changes to Childhood Vaccination Recommendations (Insider Monkey)
Jan-23-26 10:12AM	Vaxcyte Pushes Next-Gen Pneumococcal Vaccine Into Phase 3 Phase (Benzinga)
Jan-22-26 05:00PM	Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine (GlobeNewswire) +7.19%
Dec-22-25 08:19AM	This Pharma Stock Had a Rough Year. Why One Analyst Thinks It Can Rise 250%. (Barrons.com)
06:50AM	What Makes Vaxcyte (PCVX) So Attractive (Insider Monkey)
Dec-08-25 07:00AM	Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults (GlobeNewswire)
Dec-02-25 09:40AM	Vaccine Stocks Fall After FDA Plans to Impose Stricter Vaccine Rules (Zacks)
Dec-01-25 04:41PM	Moderna Slammed By 'Fear, Confusion' After FDA Alleges Covid Shots Killed 10 (Investor's Business Daily) -8.24%
12:35PM	Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men (MarketWatch)
09:36AM	Loading…
09:36AM	Moderna Falls as FDA Vows to Impose New Vaccine Requirements (Bloomberg)
Nov-18-25 09:32AM	These 3 Stocks Are Using Buybacks to Signal Market Confidence (MarketBeat)
Nov-10-25 08:16PM	TD Cowen Reiterates "Buy" Rating on Vaxcyte (PCVX) With $50 PT (Insider Monkey) +6.38%
Nov-04-25 04:05PM	Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study (GlobeNewswire)
Oct-08-25 12:57AM	Bank of America Securities Maintains a Buy Rating on Vaxcyte (PCVX) (Insider Monkey)
Sep-30-25 02:49PM	What Does Wall Street Think About Vaxcyte (PCVX)? (Insider Monkey)
08:30AM	Vaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services (GlobeNewswire)
04:12AM	Vaxcyte, Inc. (PCVX) Announces Progress in its VAX-31 Infant Vaccine Study (Insider Monkey)
Sep-12-25 08:55AM	TSCM U.S. Small Cap Growth Strategy Exited Vaxcyte (PCVX) as Its Infant Trial was Less Than Compelling (Insider Monkey)
Sep-03-25 07:30AM	Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose (GlobeNewswire)
Aug-06-25 04:05PM	Vaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) (GlobeNewswire) -9.06%
Jul-31-25 11:35AM	Vaxcyte, Inc. (PCVX)'s VAX-24 Achieves Phase 2 Success in Infants (Insider Monkey)
Jul-16-25 09:38AM	Mizuho Maintains an Overweight Rating on Vaxcyte (PCVX) (Insider Monkey)
Jul-08-25 08:17AM	Here's Why Vaxcyte (PCVX) Sold Off in Q1 (Insider Monkey)
Jul-02-25 02:47AM	Cantor Fitzgerald Maintains Overweight on Vaxcyte Amid Vaccine Development and ACIP Meeting (Insider Monkey)
09:08AM	Loading…
May-27-25 09:08AM	Here's Why Vaxcyte (PCVX) Sold Off in Q1 (Insider Monkey)
May-09-25 09:03AM	Is Vaxcyte, Inc. (PCVX) The Best Stock That Will Bounce Back? (Insider Monkey)
May-07-25 04:01PM	Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) +8.45%
04:55AM	Fidelity Select Health Care Portfolio Q1 2025 Commentary (Seeking Alpha)
May-03-25 05:30AM	Franklin Growth Opportunities SMA Q1 2025 Commentary (Seeking Alpha)
May-01-25 08:00AM	Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors (GlobeNewswire)
Apr-30-25 06:33PM	Hope Amidst The Madness As Market Avoids A New Low (Seeking Alpha)
Apr-29-25 08:24PM	Is Vaxcyte, Inc. (PCVX) the Best Oversold NASDAQ Stock to Buy Right Now? (Insider Monkey) +5.68%
Apr-11-25 04:21PM	Vaxcyte, Inc. (PCVX): Billionaire Stanley Druckenmiller's Top Stock Pick with Huge Upside Potential (Insider Monkey) +11.27%
Apr-10-25 01:07PM	Vaxcyte Stock Plummets 56% in a Month: Here's the Reason (Zacks) -8.96%
Apr-07-25 08:00AM	ClearBridge Small Cap Growth Strategy Q1 2025 Commentary (Seeking Alpha)
Apr-05-25 11:00AM	Markets Watch Out For Core CPI With Big Banks Set To Report Earnings (Seeking Alpha)
Apr-01-25 12:45PM	Vaxcyte narrow misses in Phase 2 likely to be ok in Phase 3, says Evercore ISI (TipRanks) -14.65%
12:16PM	Rocket acquires Mr. Cooper, Musks xAI acquires X: Morning Buzz (TipRanks)
07:23AM	Biotech Stocks Fall After Top FDA Official Quits Over Clash With RFK Jr. (Zacks)
07:19AM	Vaxcyte stock sinks despite Phase II IPD vaccine trial success (Clinical Trials Arena)
Mar-31-25 05:20PM	Vaxcyte: Shares Tanking On Positive Data? Bad Time To Be A Vaccine Developer (Seeking Alpha) -45.64%
04:12PM	Biotechs Hammered After FDA Official Resigns, Citing RFK Jr.'s 'Misinformation And Lies' (Investor's Business Daily)
03:39PM	Vaxcyte: Plunge On FDA Top Regulator Resigning Generates Buying Opportunity (Seeking Alpha)
09:57AM	Moderna, biotech stocks slide on resignation of FDA official Peter Marks (Yahoo Finance)
09:57AM	Moderna, biotech stocks slide following resignation of FDA official Peter Marks (Yahoo Finance)
09:45AM	Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks Resigns (Investor's Business Daily)
07:00AM	Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study (GlobeNewswire)
Mar-30-25 06:30PM	Vaxcyte, Inc. (PCVX): One of the Best Debt Free Mid Cap Stocks to Buy Now (Insider Monkey)
05:00PM	Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study (GlobeNewswire)
04:08PM	Why Vaxcyte, Inc. (PCVX) Is Among the Best Mid Cap Biotech Stocks to Buy (Insider Monkey)
Mar-27-25 11:34AM	Merck Gets EC Nod for 21-Valent Pneumococcal Jab Capvaxive (Zacks)
09:44AM	Is Vaxcyte, Inc. (PCVX) the Best Up and Coming Stock to Buy According to Wall Street Analysts? (InsiderMonkey)
Mar-25-25 08:02AM	Vaxcyte (PCVX) Struggled Amid Political Uncertainty (InsiderMonkey)
Mar-20-25 12:00PM	Lazard US Equity Concentrated Portfolio Q4 2024 Commentary (SeekingAlpha)
Mar-07-25 05:35AM	Goldman Sachs Says Its Time to Pull the Trigger on Healthcare Stocks Here Are 2 Names to Pounce on Now (TipRanks)
Mar-03-25 06:50PM	Vaxcyte, Inc. (PCVX): Among the Cash-Rich Mid Cap Stocks to Buy Now (Insider Monkey)
Feb-26-25 11:03AM	Why Vaxcyte, Inc. (PCVX) Is One of the Best Vaccine Stocks to Buy According to Hedge Funds (Insider Monkey)
07:26AM	Q4 2024 Vaxcyte Inc Earnings Call (Thomson Reuters StreetEvents)
02:15AM	Vaxcyte Inc (PCVX) Q4 2024 Earnings Call Highlights: Strong Financial Health and Promising ... (GuruFocus.com)
Feb-25-25 04:01PM	Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
12:30PM	Vaxcyte, Inc. (PCVX): Among the Stocks That Will Go to The Moon According to Analysts (Insider Monkey)
Feb-13-25 04:14PM	It's Official: The Senate Will Let Robert F. Kennedy Jr. 'Go Wild' On Health Care (Investor's Business Daily)
Feb-12-25 04:05PM	Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025 (GlobeNewswire)
01:25PM	RFK Jr. Confirmation Looms. How Kennedy Could 'Go Wild' On Health Care. (Investor's Business Daily)
Feb-08-25 09:22AM	Why Vaxcyte, Inc. (PCVX) Is Among the Best Healthcare Stocks To Buy According to Analysts (Insider Monkey)
Feb-06-25 08:20AM	Vaxcyte advances second stage of Phase 2 study evaluating VAX-31 (TipRanks)
07:22AM	Vaxcyte enters final stage of Phase II pneumococcal vaccine trial in infants (Clinical Trials Arena)
Feb-05-25 08:00AM	Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants (GlobeNewswire)
Jan-30-25 04:05PM	Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Jan-18-25 05:50PM	Why Vaxcyte, Inc. (PCVX) Is One of the Best Russell 2000 Stocks to Invest in According to Analysts? (Insider Monkey)
Dec-23-24 10:11AM	Is Vaxcyte, Inc. (PCVX) the Best Performing Biotech Stock in 2024? (Insider Monkey)
Dec-09-24 07:57AM	What Makes Vaxcyte (PCVX) An Investment Bet? (Insider Monkey)
Dec-04-24 10:03AM	Vaxcyte doses first subject in pneumococcal conjugate vaccine trial in infants (Clinical Trials Arena)
Dec-03-24 08:00AM	Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants (GlobeNewswire)
Nov-27-24 09:29AM	Vaxcyte (PCVX) Surged On Positive Phase 2 Data For Its Drug (Insider Monkey)
Nov-12-24 07:30AM	Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs (GlobeNewswire)
Nov-06-24 12:09AM	Decoding Vaxcyte Inc (PCVX): A Strategic SWOT Insight (GuruFocus.com)
Nov-05-24 04:01PM	Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-01-24 09:13AM	Should You Consider Investing in Vaxcyte (PCVX)? (Insider Monkey)
Sep-14-24 07:47PM	Vaxcyte, Inc. (PCVX): Among Hedge Funds Top Biotech Stock Picks (Insider Monkey)
Sep-11-24 04:05PM	Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference (GlobeNewswire)
Sep-06-24 04:05PM	Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
07:00AM	Obesity drug startup raises $67M; Vors shielded transplant shows promise (BioPharma Dive)
Sep-04-24 11:58PM	Vaxcyte Announces Pricing of $1.3 Billion Public Offering (GlobeNewswire)
Sep-03-24 06:06PM	Vaccine Maker Raising $1 Billion Leads Post-Holiday Share Sales (Bloomberg) +36.39%
04:09PM	Vaxcyte Catapults As It Looks To Take On Pfizer, Merck In A Massive Market (Investor's Business Daily)
04:01PM	Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
01:22PM	Heard on the Street: Pfizer Better Watch Out for This Biotech (The Wall Street Journal)
11:43AM	Biotech Startup Vaxcyte Is a Threat to Pfizer and Merck. A Vaccine Candidate Is Why. (Barrons.com)
10:48AM	Look Out, Pfizer and Merck. Vaxcyte Posts Strong Pneumococcal Vaccine Data. (Barrons.com)
09:40AM	Bacterial Infections Vaccine Developer Vaxcyte's Pneumococcal Shot Shows Promise in Mid-Stage Trial, Stock Shoots Higher (Benzinga)
09:07AM	Vaxcyte Catapults 34% As It Looks To Take On Pfizer In A $10 Billion Market (Investor's Business Daily)
08:10AM	Vaxcytes best-case data for pneumococcal vaccine boost shares (BioPharma Dive)
07:07AM	Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older (GlobeNewswire)

Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through the Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering and Jeff Fairman on November 27, 2013, and is headquartered in San Carlos, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dhaliwal Harpreet S.	Chief Technical Ops Officer	Dec 31 '25	Sale	46.69	9,743	454,891	23,928	Jan 02 04:21 PM
HARPREET DHALIWAL	Officer	Dec 31 '25	Proposed Sale	46.69	9,743	454,893		Dec 31 04:32 PM
Cowan Elvia	SVP, FINANCE	Dec 23 '25	Sale	47.92	11,623	556,972	14,534	Dec 29 05:49 PM
ELVIA COWAN	Officer	Dec 23 '25	Proposed Sale	47.92	11,623	556,972		Dec 23 04:04 PM
Lukatch Heath	Director	Apr 08 '25	Option Exercise	16.78	7,000	117,490	14,175	Apr 10 08:06 AM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Apr 07 '25	Option Exercise	20.93	4,777	99,983	131,950	Apr 09 08:05 AM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Apr 04 '25	Option Exercise	8.96	20,533	183,888	518,775	Apr 07 07:38 AM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Mar 05 '25	Option Exercise	21.41	5,000	107,050	46,620	Mar 07 04:43 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Mar 05 '25	Sale	70.74	5,000	353,699	41,620	Mar 07 04:43 PM
Eydelman Mikhail	Officer	Mar 05 '25	Proposed Sale	68.87	5,000	344,350		Mar 05 04:10 PM
Wassil Jim	CHIEF OPERATING OFFICER	Mar 03 '25	Option Exercise	4.38	8,000	35,071	162,931	Mar 03 09:14 PM
Wassil Jim	CHIEF OPERATING OFFICER	Mar 03 '25	Sale	73.27	8,000	586,165	154,931	Mar 03 09:14 PM
Wassil Jim	Officer	Mar 03 '25	Proposed Sale	73.17	8,000	585,360		Mar 03 04:06 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Feb 18 '25	Option Exercise	5.35	8,000	42,800	117,491	Feb 19 06:04 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Feb 18 '25	Sale	83.85	8,000	670,823	109,491	Feb 19 06:04 PM
GUGGENHIME ANDREW	Officer	Feb 18 '25	Proposed Sale	102.08	8,000	816,640		Feb 18 04:29 PM

ARQT

Arcutis Biotherapeutics Inc

PCVX

Vaxcyte Inc

Upgrade your FINVIZ experience